LOGIN
OTA 2023: Reducing Opioid Use and Pain in Polytrauma Patients with Low-Dose, Short-Term IV Ketorolac
October 2023
OTA 2023: Reducing Opioid Use and Pain in Polytrauma Patients with Low-Dose, Short-Term IV Ketorolac
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A
Low-Dose Short-term Scheduled Ketorolac Reduced Opioid Use and Pain in Orthopaedic Polytrauma Patients: A Randomized Clinical Trial
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
70 orthopaedic polytrauma patients were randomized to receive 5 days of intravenous low-dose ketorolac (n=35) or a placebo (n=35). The main outcomes of interest included length of stay, opioid consumption, and post-operative pain scores. The ketorolac group did not show any advantage in length of stay outcome compared to placebo, but reported significantly lower opioid consumption and pain scores ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.